Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma
Lafutidine changes levels of somatostatin, calcitonin gene-related peptide, and secretin in human plasma
复制标题
DOI：
10.1248/bpb.25.379
复制
发表时间：
2002-03-01
影响因子：
2
通讯作者：
Takeyama, M
中科院分区：
文献类型：
--
作者：
Itoh, H;Naito, T;Takeyama, M
我们研究了组胺H-2受体拮抗剂Lafutidine对胃肠道肽水平（降钙素基因基因相关肽（CGRP），胃蛋白酶，Secretin和Motilin）对健康受试者的血浆的影响。单一口服Lafutidine（10 mg）后，在给药后60分钟的样本中，血浆Lafutidine水平（186 +/- 13.4 ng/mL）最高，然后血浆水平下降。与安慰剂组相比，Lafutidine在20至120分钟时在20至120分钟时导致血浆生长抑素水平显着增加，而在40至120分钟的CGRF水平上则显着增加。血浆分泌蛋白的生理释放减少了Lafutidine，但该药物没有改变胃蛋白或Motilin的水平。这些结果表明，拉富丁氨酸对胃肠道功能的调节的药理作用与人血浆中生长抑素，CGRP-和sectionin-免疫反应水平的变化密切相关。
We examined the effects of the histamine H-2-receptor antagonist, lafutidine, on the levels of gastrointestinal peptides (somatostatin, calcitonin gene-related peptide (CGRP), gastrin, secretin, and motilin) in plasma from healthy subjects. After a single oral administration of lafutidine (10 mg), the plasma lafutidine level (186+/-13.4 ng/ml) was highest in the 60-min sample after administration and then the plasma level fell. Lafutidine caused significant increase in plasma somatostatin levels at 20 to 120 min and in CGRF levels at 40 to 120 min, compared with a placebo group. The physiological release of plasma secretin was reduced by administration of lafutidine, but the medicine did not alter the level of gastrin or motilin. These results suggest that the pharmacological effects of lafutidine on regulation of gastrointestinal functions closely relate to changes of somatostatin-, CGRP- and secretin-immunoreactive substance levels in human plasma.